 price
rais nextseq unlik
thesi updat share pressur better
part posit pre-a launch new nextseq
system hint potenti relief around
corner bull unfortun think rais
question answer shape anoth year
load ramp instrument side soft rev rais
question asp commentari around novaseq declin
potenti paus amongst low throughput lt custom evalu
new nextseq temper expect revenu ramp
management also note hiseq decommiss
use rais question whether market excess capac new
system increas instal base consum side
pull-through guidanc flat yoy hiseq
continu declin impli popseq project key driver
consum acceler teen math suggest
popseq could drive bp consum growth
impli base growth flattish yoy right
popseq sampl doubl
sustain momentum tough ask visibl popseq
tricki lastli guid lsd revenue growth like impact
de-stock custom work inventori older system
step cdx deal impli trajectori
tougher comp think rais number question
answer clear visibl current given
lower pt equat price-to-earnings similar
went product cycl transit
multipl compress low
pleas see guidanc color market color cc
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
step
array declin due on-going dtc weak dtc rep total array rev
china high teen driven clinic sequenc
gross margin line
tax rate higher one-tim discret benefit
novaseq pull-thru mm rang
revenu mm custom adjust plan launch nextseq
adj opex revenue bp y/i
america sequenc consum ivd off-set dtc
emea due uk biobank ramp
china due easi comp tariff stock
market driven clinic esp oncolog
excit opportun clinic oncolog ahead
sequenc consum shipment clinic incl oncolog repro health genet diseas etc
inc adopt driven cdx test like foundationon gh
oncolog repres total sequenc consum
repro health sequenc consum driven nipt adopt
veriseq nipt emea sampl volum growth
sequenc consum relat genet diseas test
nextseq dx remain strong custom like look new launch nextseq
sequenc servic y/i driven roch deal off-set gel declin
array due dtc hw off-set genet diseas research
gm bp y/i due product mix higher ivd licens partial off-set lower dtc servic
tax rate increas due incom mix variou tax jurisdict
repod mm stock mm left current plan
sequenc servic driven roch deal off-set gel declin
roch mileston came mm better expect
corona viru use mani step track diagnosi
clinic portfolio tso trusight nipt continu progress thru regulatori
flow cell track yr-end launch
novaseq pull-thru mm per system
pipelin current focus smaller lab
expect mm rang
lower pull-thru due emerg mkt mix lower unit order unit order vs multipl
custom transit novaseq far
expect lower novaseq placement come yr upgrad cycl
ship novaseq
nextseq pull-thru q/q low end target rang
expect ship nextseq
mostli replac nextseq w/ small miseq high throughput custom
throughput system rev came expect primarili due miniseq
nextseq dx repres shipment vs last yr
uk biobank run full scale
allofu track start mid-yr
nh track start mid-yr
smaller project began begin
compani note dont realli move needl
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari
analyst luke sergott vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
